

REGIONAL ADULT PARENTERAL DRUG MONOGRAPH

GENERIC NAME

remifentanil



Effective Date: Mar12-2014

CLASSIFICATION

OTHER NAMES

PAGE

Revised Date:

Narcotic Analgesic

Ultiva

1 of 2

ADMINISTRATION POLICY:

IV bolus: Administration restricted to anesthetist in OR
IV Infusion: Administration restricted to anesthetist in OR

RECONSTITUTION/DILUTION/ADMINISTRATION:

Available as:

1 mg vial: Add 1 mL sterile water for injection

Final Volume: 1 mL

Final Concentration: 1 mg/mL

2 mg vial:

Add 2 mL sterile water for injection

Final Volume: 2 mL

Final Concentration: 1 mg/mL

IV bolus: May be administered over 30 to 60 seconds.

Maximum rate: IV bolus: 100 mcg/minute

Maximum concentration: 1 mg/mL

DOSAGE:

NOTE: Dose titration of remifentanil to be done by anesthetist ONLY

Induction of anesthesia: 0.5 to 1 mcg/kg/minute; if endotracheal intubation is to occur in less than 8 minutes, an intial dose of 1 mcg/kg may be given over 30 to 60 seconds.

Maintenance of anesthesia: Supplemental bolus dose of 1 mcg/kg may be administered every 2 to 5 minutes. Consider increasing concomitant anesthetics with infusion rate greater than 1 mcg/kg/minute. Infusion rate can be titrated upward in increments of 25% to 100% or downward in decrements of 25% to 50%. May titrate every 2 to 5 minutes.

With nitrous oxide (66%): 0.4 mcg/kg/minute (range: 0.1-2 mcg/kg/minute)

With isoflurane: 0.25 mcg/kg/minute (range: 0.05-2 mcg/kg/minute)

With propofol: 0.25 mcg/kg/minute (range: 0.05-2 mcg/kg/minute)

Continuation as an analgesic in immediate postoperative period:

0.1 mcg/kg/minute (range: 0.025 to 0.2 mcg/kg/minute)

Infusion rate be adjusted every 5 minutes in increments of 0.025 mcg/kg/minute.

Bolus doses are not recommended.

Infusion rates greater than 0.2 mcg/kg/minute are associated with respiratory depression.

Maximum daily dose: n/a

STABILITY/COMPATIBILITY:

Stability of reconstituted solution: 24 hours at room temperature **Stability of Final Admixture:** 24 hours at room temperature

Compatibility: Compatible with D5W, normal saline, dextrose/saline solutions



REGIONAL ADULT PARENTERAL DRUG MONOGRAPH

GENERIC NAME

remifentanil



Effective Date: Mar12-2014	CLASSIFICATION	OTHER NAMES	PAGE
Revised Date:	Narcotic Analgesic	Ultiva	2 of 2

PRECAUTIONS, POTENTIAL ADVERSE REACTIONS:

• Respiratory depression/apnea (hypoxia, hypercapnia, decreased respiratory rate, apnea), decreased level of consciousness, hypotension, nausea/vomiting, dysphoria, bradycardia, sleepiness, pruritis, muscle rigidity)

ADDITIONAL NOTES AND NURSING CONSIDERATIONS:

- Patients should have continuous oxygen saturation monitoring
- Continuous patient monitoring by a nurse is based on individual patient assessment
- Within 5 to 10 minutes after discontinuation of remifentanil, no residual analysesic activity will be present.
- The peak time to effective analgesia after a single dose is 1 to 3 minutes.
- Elderly patients have an increased sensitivity to effect of remifentanil; doses should be decreased by 50% and titrated.